GlassScriptPhysician profile
Robin Michelle Cook
NPI 1205592243
$2,542.18
in general payments reported to CMS, 2019-2025
21 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $640 · 2023: $1,278 · 2024: $624.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,635 · Education: $267.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,634.90 |
| Education | $266.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $485.00 | 2022-2024 | Xospata, Cresemba |
| Pharmaessentia USA Corporation | $241.08 | 2022-2024 | Besremi |
| Celgene Corporation | $225.77 | 2022-2024 | Reblozyl, Onureg, Sprycel |
| Abbvie INC. | $207.03 | 2022-2024 | |
| Cti Biopharma Corp. | $185.78 | 2022-2023 | Vonjo |
| Astrazeneca Pharmaceuticals LP | $138.42 | 2022-2023 | Calquence |
| Incyte Corporation | $137.62 | 2022-2023 | Jakafi |
| Adaptive Biotechnologies Corporation | $102.33 | 2023-2024 | Clonoseq |
| Novartis Pharmaceuticals Corporation | $100.51 | 2022-2023 | |
| Amgen INC. | $100.11 | 2022-2023 | Blincyto |
| Lilly USA, LLC | $98.98 | 2023-2024 | Jaypirca |
| Rigel Pharmaceuticals, INC. | $84.55 | 2023-2024 | Rezlidhia, Tavalisse |
| Daiichi Sankyo INC. | $83.51 | 2023-2024 | Vanflyta |
| Pfizer INC. | $82.24 | 2023-2024 | |
| Merck Sharp & Dohme LLC | $77.26 | 2023 | Zerbaxa, Recarbrio, Dificid |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Servier Pharmaceuticals LLC | $49.60 | 2022-2023 | |
| Blueprint Medicines Corporation | $48.82 | 2022-2023 | Ayvakit |
| Janssen Biotech, INC. | $27.54 | 2024 | Imbruvica |
| Beigene USA, INC. | $24.06 | 2023 | Brukinsa |
| Taiho Oncology, INC. | $23.11 | 2023 | |
| Sobi, INC | $18.86 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robin Cook listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.